GlassScriptPhysician profile
Joseph Gnanaraj
NPI 1720262736
$2,531.75
in general payments reported to CMS, 2019-2025
9 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2021: $15.47 · 2022: $41.28 · 2023: $1,971 · 2024: $146 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Travel and Lodging: $1,065 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.23 |
| Travel and Lodging | $1,064.67 |
| Education | $138.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,900.23 | 2023-2025 | Accent, Aveir, Confirm Rx |
| Astrazeneca Pharmaceuticals LP | $138.72 | 2023 | Breztri |
| Novo Nordisk INC | $126.68 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $115.32 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $81.74 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $30.68 | 2025 | Camzyos |
| Boston Scientific Corporation | $26.28 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gnanaraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.